# Halozyme Therapeutics, Inc.: Form 8-K, filed Sep 22, 2026

- Company: [Halozyme Therapeutics, Inc.](/companies/halo.md) (CIK 1159036)
- Form: 8-K
- Filed: 2026-09-22
- Accepted by EDGAR: Sep 22, 2026, 16:41 ET
- Period: 2026-09-22
- Accession: 0001193125-26-398015
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1159036/000119312526398015/d148460d8k.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1159036/000119312526398015/

## Items reported

- Item 1.01: Entry into a material agreement
- Item 2.03: New direct financial obligation
- Item 3.02: Unregistered sale of equity
- Item 9.01: Financial statements and exhibits

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1159036/000119312526398015/d148460d8k.htm

Filed Sep 22, 2026.
Source: SEC EDGAR, the filing index for accession 0001193125-26-398015. Last ingested by Listed: Nov 5, 2026, 17:46 ET. No prices; not investment advice.
